BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2024 3:02:15 AM | Browse: 203 | Download: 746
 |
Received |
|
2024-05-29 22:06 |
|
Peer-Review Started |
|
2024-05-29 22:06 |
|
First Decision by Editorial Office Director |
|
2024-08-15 19:46 |
|
Return for Revision |
|
2024-08-15 19:46 |
|
Revised |
|
2024-08-28 07:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-23 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-23 10:43 |
|
Articles in Press |
|
2024-09-23 10:43 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-30 10:54 |
|
Publish the Manuscript Online |
|
2024-10-25 03:02 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mohamed Abdel-Samiee, Essam Salah Ibrahim, Mohamed Kohla, Eman Abdelsameea and Mohsen Salama |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eman Abdelsameea, MD, Full Professor, Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom 32511, Egypt. eabdelsameea@liver-eg.org |
| Key Words |
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Myofibroblasts; Fibrosis; Antifibrotic pharmacotherapy; Nonalcoholic fatty liver disease treatment strategies; Emerging treatments for nonalcoholic steatohepatitis |
| Core Tip |
Non-alcoholic fatty liver disease (NAFLD) global incidence is escalating significantly. NAFLD covers a range of liver conditions, from simple steatosis to the more severe form known as non-alcoholic steatohepatitis, which involves chronic liver inflammation and the transformation of hepatic stellate cells into myofibroblasts that generate excess extracellular matrix, leading to fibrosis. Hepatocyte ballooning is a key catalyst for fibrosis progression. |
| Publish Date |
2024-10-25 03:02 |
| Citation |
Abdel-Samiee M, Ibrahim ES, Kohla M, Abdelsameea E, Salama M. Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis. World J Gastrointest Pharmacol Ther 2024; 15(6): 97381 |
| URL |
https://www.wjgnet.com/2150-5349/full/v15/i6/97381.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v15.i6.97381 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
